These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Bioresorbable coronary stent for the treatment of complex coronary lesions: Data from an all-comer registry. Cuculo A; Ruggiero A; Centola A; Campanale G; Passero T; Gaglione A; Di Biase M; Brunetti ND Int J Cardiol; 2017 Mar; 230():136-141. PubMed ID: 28038806 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Serruys PW; Onuma Y; Ormiston JA; de Bruyne B; Regar E; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Miquel-Hebert K; Rapoza R; García-García HM Circulation; 2010 Nov; 122(22):2301-12. PubMed ID: 21098436 [TBL] [Abstract][Full Text] [Related]
24. Everolimus-eluting bioresorbable vascular scaffolds versus second generation drug-eluting stents for percutaneous treatment of chronic total coronary occlusions: Technical and procedural outcomes from the GHOST-CTO registry. La Manna A; Chisari A; Giacchi G; Capodanno D; Longo G; Di Silvestro M; Capranzano P; Tamburino C Catheter Cardiovasc Interv; 2016 Nov; 88(6):E155-E163. PubMed ID: 26756959 [TBL] [Abstract][Full Text] [Related]
33. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries). Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443 [TBL] [Abstract][Full Text] [Related]
34. Use of a bioresorbable novolimus eluting vascular scaffold fails a hybrid PCI strategy with drug eluting stent. Schneider VS; Skurk C; Riedel M; Abdelwahed YS; Landmesser U; Leistner DM Clin Res Cardiol; 2017 Jul; 106(7):557-559. PubMed ID: 28374059 [No Abstract] [Full Text] [Related]
35. Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial. Diletti R; Farooq V; Girasis C; Bourantas C; Onuma Y; Heo JH; Gogas BD; van Geuns RJ; Regar E; de Bruyne B; Dudek D; Thuesen L; Chevalier B; McClean D; Windecker S; Whitbourn RJ; Smits P; Koolen J; Meredith I; Li X; Miquel-Hebert K; Veldhof S; Garcia-Garcia HM; Ormiston JA; Serruys PW Heart; 2013 Jan; 99(2):98-105. PubMed ID: 23118346 [TBL] [Abstract][Full Text] [Related]
36. Coronary artery perforation at the level of two-overlapping bioresorbable vascular scaffolds: The importance of vessel sizing and scaffold thickness. Pichette M; Chevalier F; Généreux P Catheter Cardiovasc Interv; 2015 Oct; 86(4):686-91. PubMed ID: 26122768 [TBL] [Abstract][Full Text] [Related]
37. The use of bioresorbable vascular scaffold Absorb BVS® in patients with stable coronary artery disease: one-year results with special focus on the hybrid bioresorbable vascular scaffolds and drug eluting stents treatment. Gil RJ; Bil J; Pawłowski T; Yuldashev N; Kołakowski L; Jańczak J; Jabłoński W; Paliński P Kardiol Pol; 2016; 74(7):627-33. PubMed ID: 26779846 [TBL] [Abstract][Full Text] [Related]
38. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961 [TBL] [Abstract][Full Text] [Related]
39. Bailout left main bioresorbable vascular scaffolding for the treatment of iatrogenic coronary dissection induced by guiding catheter and sticky ABSORB bioresorbable vascular scaffold balloon. Yew KL Int J Cardiol; 2015; 187():527-9. PubMed ID: 25846666 [No Abstract] [Full Text] [Related]
40. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. Ormiston JA; Serruys PW; Onuma Y; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Garcia-Garcia HM Circ Cardiovasc Interv; 2012 Oct; 5(5):620-32. PubMed ID: 23048057 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]